Pure Encapsulations, a leading manufacturer of hypoallergenic nutritional supplements, announces the findings of two studies utilizing Pure Encapsulations Resveratrol. Conducted by academic researchers, these independent clinical investigations diverged from prior research studies on resveratrol by evaluating the product at a once-daily dose.
Since the 1990s, scientists have known that resveratrol moderates nuclear factor kappa B (NFκB), a master switch of cytokine gene expression in cell culture. Dozens of studies have since attributed this mechanism to its cardioprotective and neuroprotective effects. However, these clinical studies used high doses, typically 100 to 500 mg per day, leaving questions about the ability of resveratrol to provide support at a lower dose.
"While the clinical value of resveratrol is widely recognized, health care professionals must navigate an overwhelming array of formulations and doses,” states Kelly Heim, Ph.D., a pharmacologist at Pure Encapsulations. “The new studies on Pure Encapsulations’ Resveratrol allow the practitioner to select and apply our product with confidence. This research is among many examples of Pure Encapsulations’ alignment with evidence-based medicine.”
In the first randomized, placebo-controlled study, researchers from the State University of New York at Buffalo examined the effect of one capsule, providing 40 mg resveratrol daily, on oxidative and immunologic markers in healthy human subjects. The results, published in The Journal of Clinical Endocrinology and Metabolism (2010) indicated statistically significant and favorable changes in oxidative stress and levels of cytokines, such as TNF-alpha and interleukin-6, after three weeks.
The second randomized, placebo-controlled study, conducted at Tehran University of Medical Sciences in Tehran, Iran, evaluated the effects of the same dose on cytokine levels in professional basketball players over an intense 6-week training period. The results, published in The International Journal of Preventive Medicine (2013) indicated statistically significant moderation of TNF-alpha and interleukin-6 in the group receiving resveratrol relative to placebo.
“Concerns about the bioavailability of resveratrol have driven many researchers to use high doses of isolated forms for the clinical trials,” states Dr. Heim. “However, these two studies show that a low dose from a natural plant source can deliver measurable results in a matter of weeks.”